Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Decnupaz Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0861

    Decnupaz (pivekimab sunirine-pvzy) prior authorization and coverage

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0861 alerts

    Get alerted when Policy IC-0861 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, clinical criteria, coding, and renewal rules for intravenous Decnupaz (pivekimab sunirine-pvzy) for adults with CD123‑expressing Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Applies to Viva Health benefit administration.

    Policy Summary
    PayerViva Health
    PolicyDecnupaz (pivekimab sunirine-pvzy) prior authorization and coverage
    Policy CodePolicy IC-0861
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for Decnupaz; initial approvals valid for 6 months and may be renewed every 6 months with documentation of CD123-positive BPDCN and monitoring for hepatotoxicity and infusion‑related reactions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial prior authorization duration
    6 mgmaximum per dose (3 vials)
    every 21 daysdosing interval
    >=18

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    minimum patient age for coverage
    J9999, C9399billing HCPCS codes

    Coverage Criteria for Decnupaz (pivekimab sunirine-pvzy)

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Initial BPDCN criteria: Member is at least 18 years of age; AND CD123-positive/expressing disease (patients previously treated with CD123-targeting agents must still have blasts with detectable CD123 expression); AND used as single-agent therapy; AND member will be monitored for severe infusion-related reactions, hypersensitivity reactions, and new or worsening edema; AND no history of hepatic veno-occlusive disease (VOD) and close monitoring (including liver function testing such as ALT, AST, total bilirubin prior to each dose); AND no active or suspected central nervous system (CNS) disease involvement; AND has a definitive diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); AND agent is used as first-line therapy for treatment-naïve de novo BPDCN OR used for relapsed/refractory BPDCN.age >=18

    Dose per dosing section; calculate by actual body weight; recommended 0.045 mg/kg IV once every 21 days until disease progression or unacceptable toxicity.

    Continuation/Renewal Therapy — Renewal approval criteria

    Renewal approval may be granted when ALL of the following are met:

    Renewal criteria: Member continues to meet universal and indication-specific criteria (including relevant concomitant therapy requirements and performance status as identified in initial criteria); AND absence of unacceptable toxicity from the drug (examples include severe hepatotoxicity including VOD, severe infusion-related reactions, severe edema, severe hypersensitivity reactions); AND disease stabilization or improvement as evidenced by complete response (CR) or clinical complete response (CRc).renewal every 180 days

    Prior authorization validity may be renewed every 6 months.

    Per policy, patients with active or suspected central nervous system (CNS) disease involvement are excluded from coverage for Decnupaz. The universal criteria explicitly state that the member must not have active or suspected CNS disease involvement as a condition of authorization.

    A history of hepatic veno-occlusive disease (VOD) is a contraindication to coverage under this policy. The universal criteria require that the member does not have prior VOD and specify that members must undergo close monitoring for signs and symptoms of VOD, including liver function testing (e.g., ALT, AST, total bilirubin) prior to each dose.

    Initial Authorization Criteria (BPDCN)

    Initial Therapy (BPDCN)

    Initial authorization criteria specific to BPDCN — covered when ALL of the following are met:

    Initial therapy BPDCN: Adult (>=18 years of age); AND CD123-positive disease (patients who received prior CD123-targeting agents must still have blasts with detectable CD123 expression); AND used as single-agent therapy; AND a monitoring plan is in place for severe infusion-related reactions, hypersensitivity reactions, and new or worsening edema; AND no history of hepatic veno-occlusive disease (VOD) with plan for close monitoring including liver function tests prior to each dose; AND no active or suspected CNS disease involvement; AND definitive diagnosis of BPDCN; AND used as first-line therapy for treatment‑naïve de novo BPDCN OR used for relapsed/refractory BPDCN.

    Dose: 0.045 mg/kg IV every 21 days; calculate by actual body weight; initial prior authorization valid for 180 days.

    Continuation and Renewal Rules

    Continuation Therapy

    Renewal/continuation approval criteria — continued coverage may be granted when ALL of the following are met:

    Continuation: Member continues to meet universal and indication-specific criteria; AND absence of unacceptable toxicity from the drug (examples include severe hepatotoxicity including VOD, severe infusion-related reactions, severe edema, severe hypersensitivity reactions); AND evidence of disease stabilization or improvement (complete response [CR] or clinical complete response [CRc]).

    Prior authorization renewals every 180 days.

    Provider Requirements and Administrative Actions

    Prior Authorization

    Prior authorization required — initial approvals valid 6 months

    Prior authorization is required for Decnupaz for BPDCN in adults; initial authorizations are valid for 6 months (180 days) and may be renewed every 6 months. Indication must be Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in adults (≥18 years) and used as single‑agent therapy.

    • Initial prior authorization validity: 6 months (180 days).
    • Renewals may be granted every 6 months (180 days).
    • Indication: definitive diagnosis of BPDCN in adults (≥18 years).
    • Must be used as single‑agent therapy.
    Step Therapy

    Step therapy: none required

    No prerequisite step therapy is required for Decnupaz; it may be used as first‑line therapy for treatment‑naïve de novo BPDCN or as treatment for relapsed/refractory disease as a single agent.

    Billing, NDC, and Diagnosis Codes

    HCPCS CodesHCPCS
    J9999Not Otherwise Classified, antineoplastic drugs
    C9399Unclassified drug or biologicals (Hospital Out-Patient Use)
    NDCNDC
    00074-0282-xxDecnupaz 2 mg lyophilized powder for injection in a single-dose vial
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    C86.40Blastic NK-cell lymphoma not having achieved remission
    Dose per administration — inv-08: Recommended dosing and interval
    Recommended dose0.045 mg/kg IV once every 3 weeks (21-day cycle); calculate by actual body weight
    Administration rateInfuse intravenously over approximately 15–30 minutes
    Maximum per dose6 mg (equivalent to 3 vials) per dose
    Dosing frequencyOnce every 21 days until disease progression or unacceptable toxicity

    Quantity and Dosing Limits

    Decnupaz — inv-18: Maximum per dose
    Maximum per dose6 mg (3 vials)
    Reference intervalLimit applies per dose administered every 21 days
    Quantity unitHCPCS unit reported as mg (3 vials) per dose
    StepRequirement
    1No prerequisite step therapy required; Decnupaz may be used as first‑line therapy for treatment‑naïve de novo BPDCN or as therapy for relapsed/refractory BPDCN.

    Site of Care and Billing Context

    Billing Rule

    Infusion center billing: use outpatient HCPCS; hospital outpatient code C9399 referenced

    Bill administrations in the outpatient infusion setting using the listed HCPCS/CPT outpatient codes. For hospital outpatient use, reference the unclassified hospital outpatient drug/biological code C9399; J9999 is listed for non‑classified antineoplastic drugs.

    • HCPCS codes: J9999 (Not Otherwise Classified, antineoplastic drugs).
    • Hospital outpatient code: C9399 (Unclassified drug or biologicals – Hospital Out‑Patient Use).
    • NDC available for product identification: 00074-0282-xx.

    Definitions and Key Terms

    CD123-positive disease — inv-14: Definition and prior therapy note
    DefinitionDisease with detectable CD123 expression on blasts
    Prior CD123-targeting therapyPrior treatment with CD123-targeting agents does not preclude use provided blasts remain CD123-positive
    Documentation requiredMedical record must demonstrate CD123 expression on blasts prior to therapy

    Background

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy characterized by expression of CD123. Decnupaz (pivekimab sunirine-pvzy) is an antibody–drug conjugate that targets CD123 and is used as single‑agent therapy for CD123‑expressing BPDCN. Due to risks observed with this class and the agent, monitoring is required for infusion-related reactions, hypersensitivity reactions, new or worsening edema, and for hepatic veno-occlusive disease (VOD) via liver function tests prior to each dose.

    Policy Summary
    PayerViva Health
    PolicyDecnupaz (pivekimab sunirine-pvzy) prior authorization and coverage
    Policy CodePolicy IC-0861
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for Decnupaz; initial approvals valid for 6 months and may be renewed every 6 months with documentation of CD123-positive BPDCN and monitoring for hepatotoxicity and infusion‑related reactions.
    SourceLink
    On This Page
    Coverage Criteria for Decnupaz (pivekimab sunirine-pvzy)Initial Authorization Criteria (BPDCN)Continuation and Renewal RulesProvider Requirements and Administrative ActionsBilling, NDC, and Diagnosis CodesQuantity and Dosing LimitsSite of Care and Billing ContextDefinitions and Key TermsBackground
  1. No prior failed therapy required before initiation.
  2. Permitted as first‑line (de novo) or for relapsed/refractory BPDCN.
  3. Documentation Required

    Required clinical documentation and monitoring

    Documentation must confirm CD123‑positive disease, absence of prior hepatic veno‑occlusive disease (VOD), and a monitoring plan including liver function testing prior to each dose; dosing must be calculated using actual body weight (0.045 mg/kg IV every 21 days).

    • Evidence of CD123‑positive/expression on blasts (detectable CD123).
    • Documentation that the member does not have a history of hepatic VOD.
    • Plan for close monitoring for VOD signs/symptoms, including LFTs (e.g., ALT, AST, total bilirubin) prior to each dose.
    • Dose calculation documented using actual body weight at 0.045 mg/kg IV every 21 days.
    Denial Risk

    Renewal denial risks: unacceptable toxicity or no response

    Renewal may be denied for unacceptable toxicity or lack of disease stabilization; examples of unacceptable toxicity include severe hepatotoxicity (including VOD), severe infusion‑related reactions, severe edema, or severe hypersensitivity.

    • Renewal requires absence of unacceptable toxicity; presence of listed severe toxicities may result in denial.
    • Renewal also requires evidence of disease stabilization or improvement (CR or CRc).